drugset / Trial / NCT07082868
A Study of Epcoritamab and Ibrutinib in People With Central Nervous System Lymphoma (CNSL)
Non-randomizedSequentialOpen-labelTreatment
Summary
The purpose of this study is to find out whether the combination of epcoritamab and ibrutinib is a safe treatment approach that causes few or mild side effects in people with relapsed/refractory primary central nervous system lymphoma (PCNSL) or secondary central nervous system lymphoma (SCNSL).
Timeline
- Start
- 2025-08-13
- Primary completion
- 2028-08
- Completion
- 2028-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Epcoritamab | Monoclonal antibody | — | Subcutaneous |
| Subject | Ibrutinib | Small molecule | — | — |